Cargando…

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM

Detalles Bibliográficos
Autores principales:	Wang, Y., Jain, P., Locke, F., Maurer, M., Frank, M., Munoz, J., Dahiya, S., Beitinjaneh, A., Jacobs, M., Mcguirk, J., Vose, J., Goy, A., Andreadis, C., Hill, B., Dorritie, K., Oluwole, O., Deol, A., Shah, B., Paludo, J., Wang, T., Banerjee, R., Neelapu, S., Miklos, D., Rapoport, A., Lekakis, L., Ghobadi, A., Lin, Y., Wang, M., Jain, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430474/ http://dx.doi.org/10.1097/01.HS9.0000847488.86807.da

Ejemplares similares

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022)

Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia
Publicado: (2023)

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US)
por: Locke, F., et al.
Publicado: (2022)

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT
por: Ahmed, Nausheen, et al.
Publicado: (2023)

P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT
por: Shah, Bijal, et al.
Publicado: (2023)

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
por: Ball, Graeme, et al.
Publicado: (2022)

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
por: Shah, Bijal D, et al.
Publicado: (2023)

Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease
por: Dean, Erin A., et al.
Publicado: (2023)

S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
por: Marchetti, Monia
Publicado: (2023)

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
por: Du, Kai-Xin, et al.
Publicado: (2023)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2023)

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
por: Scholler, Nathalie, et al.
Publicado: (2022)

1155. Clinical and Epidemiological Characteristics of Patients with Paracoccidioidomycosis in Asuncion Paraguay
por: Núñez, Fátima M, et al.
Publicado: (2020)

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2023)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
por: Ying, Zhitao, et al.
Publicado: (2020)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

High grade lymphoma in the nasopharynx presented as sudden onset of bilateral blindness
por: Shambhu, S, et al.
Publicado: (2004)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

1155. Excessive Movement, Unnecessary Contamination: Clostridium difficile Patients in the Hospital
por: Reese, Sara, et al.
Publicado: (2018)

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2021)

Therapeutic Vaccine for Lymphoma
por: Lee, Seung-Tae, et al.
Publicado: (2007)

1155 Origin of the dengue virus outbreak in Martin County, Florida, USA 2013
por: Ramgopal, Moti N., et al.
Publicado: (2014)

Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats
por: Li, Yanjun, et al.
Publicado: (2022)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
por: Plaks, Vicki, et al.
Publicado: (2021)

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
por: Oluwole, Olalekan O., et al.
Publicado: (2021)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
por: Lin, Y., et al.
Publicado: (2022)

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
por: Younes, A, et al.
Publicado: (2010)

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy
por: Lekakis, Lazaros J., et al.
Publicado: (2019)

1155. CAUTI Path to Zero: A Triple-Pronged Approach to Minding Our Pees and Cues
por: Henry, Sharen, et al.
Publicado: (2019)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Targeting Wnt pathway in mantle cell lymphoma-initiating cells
por: Mathur, Rohit, et al.
Publicado: (2015)

Correction: DeClercq, V.; et al. Association between Diet Quality and Adiposity in the Atlantic PATH Cohort. Nutrients 2017, 9, 1155
por: DeClercq, Vanessa, et al.
Publicado: (2018)

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

Pediatric mediastinal lymphoma
por: Mallick, Saumyaranjan, et al.
Publicado: (2020)

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
por: Russler-Germain, David A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_noslv6dkp4kk6to3ro6h2a09hh